EUVIMEDEUVIMED entdecken
Crossref

Abstract 8469: Mineralocorticoid Receptor Antagonists versus SGLT2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Propensity-Matched Real World Analysis

Mineralokortikoidrezeptor-Antagonisten versus SGLT2-Inhibitoren bei Herzinsuffizienz mit erhaltener Ejektionsfraktion: eine propensity-gematchte Real-World-Analyse

Akash Jaiswal, Kumari Monika, Vikash Jaiswal

Circulation · 02.11.2026 · 154 (Suppl_1)

DOI: 10.1161/circ.154.suppl_1.8469 ↗

Auf einen Blick

Bei HFpEF war MRA im Vergleich zu SGLT2i mit höheren Risiken für Mortalität, MACE, Herzinsuffizienz-Exazerbation und akutes Nierenversagen verbunden.

Fragestellung

Wie unterscheiden sich MRA und SGLT2i hinsichtlich 1-Jahres-Klinikoutcomes bei HFpEF?

Methode

Real-World-Analyse mit TriNetX-Daten; Erwachsene mit HFpEF; Propensity-Score-Matching 1:1; 1-Jahres-Follow-up; Cox-Modelle mit HR und 95 %-KI.

Ergebnisse

Nach Matching 1.286 Patient:innen pro Gruppe. MRA vs. SGLT2i: ACM HR 1,59 (95 %-KI 1,18–2,14), MACE HR 1,27 (1,05–1,53), HF-Exazerbation HR 1,16 (1,05–1,28), AKI HR 1,20 (1,00–1,44).

Schlussfolgerung der Autor:innen

Bei HFpEF waren MRA mit signifikant höheren Risiken für Mortalität, MACE und HF-Exazerbation im Vergleich zu SGLT2i verbunden; die Befunde sind hypothesengenerierend.

Kernaussagen

  • ACM unter MRA höher als unter SGLT2i: HR 1,59 (95 %-KI 1,18–2,14)
  • MACE und HF-Exazerbation ebenfalls unter MRA erhöht
  • Vorläufige Real-World-Daten; nur hypothesengenerierend

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Circulation, erschienen am 02.11.2026. Verfasst von Akash Jaiswal und 2 weiteren Autor:innen.

Auf einen BlickAbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Mineralocorticoid receptor antagonists (MRA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) are both guideline-directed therapies for heart failure with preserved ejection fraction (HFpEF), yet direct comparative effectiveness data remain limited. OBJECTIVES: To compare 1-year clinical outcomes between MRA and SGLT2i in patients with HFpEF using real-world data. METHODS: Using the TriNetX Global Collaborative Network (171 healthcare organizations), adults with HFpEF (ICD-10 I50.3; LVEF ≥50%; systolic HF excluded) initiating MRA (spironolactone, eplerenone, or finerenone; n=1,370) or SGLT2i (n=1,639) were identified with mutually exclusive drug exposure. Propensity score matching (1:1) on demographics, comorbidities, medications, and laboratory values yielded 1,286 patients per group. Outcomes at 1 year included all-cause mortality (ACM), major adverse cardiovascular events (MACE: AMI, stroke, ACM), HF exacerbation, acute kidney injury (AKI), ischemic stroke, and atrial fibrillation/flutter. Kaplan-Meier survival analysis and Cox proportional hazards modeling provided hazard ratios (HR) with 95% confidence intervals (CI). RESULTS: After matching, mean age was 71.7 years; 57.1% were female; mean LVEF was 61.3%. Compared withSGLT2i, MRA was associated with significantly higher risks of ACM (HR 1.59 [95% CI 1.18-2.14]; P=0.002), MACE (HR 1.27 [95% CI 1.05-1.53]; P=0.012), HF exacerbation (HR 1.16 [95% CI 1.05-1.28]; P=0.004), and AKI (HR 1.20 [95% CI 1.00-1.44]; P=0.046). Atrial fibrillation/flutter (HR 1.05 [95% CI 0.92-1.19]; P=0.461) and ischemic stroke (HR 1.39 [95% CI 0.95-2.04]; P=0.091) were comparable between groups. CONCLUSIONS: This very first real world study shows that in HFpEF patients, MRA was associated with significantly higher risks of mortality, MACE, and HF exacerbation compared with SGLT2i. These hypothesis-generating findings support SGLT2i as a potentially superior pharmacological strategy in HFpEF.

Zitieren

APA

Jaiswal, A., Monika, K., & Jaiswal, V. (2026). Abstract 8469: Mineralocorticoid Receptor Antagonists versus SGLT2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Propensity-Matched Real World Analysis. Circulation, 154(Suppl_1). https://doi.org/10.1161/circ.154.suppl_1.8469

Vancouver

Jaiswal A, Monika K, Jaiswal V. Abstract 8469: Mineralocorticoid Receptor Antagonists versus SGLT2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Propensity-Matched Real World Analysis. Circulation. 2026;154(Suppl_1). doi:10.1161/circ.154.suppl_1.8469

BibTeX
@article{Jaiswal2026,
  author = {Jaiswal, Akash and Monika, Kumari and Jaiswal, Vikash},
  title = {Abstract 8469: Mineralocorticoid Receptor Antagonists versus SGLT2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Propensity-Matched Real World Analysis},
  journal = {Circulation},
  year = {2026},
  volume = {154},
  number = {Suppl_1},
  doi = {10.1161/circ.154.suppl_1.8469}
}
Kostenlos starten →